Atlas Trials

A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD

Clinical trial NCT05972473 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05972473
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Neovascular Age-related Macular Degeneration
Start date
2023-09-21
Primary completion
2027-02-28
Enrollment
600

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.